Agilent Technologies, Inc.

A Healthcare Diagnostics & Research

Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024.

Revenue
+8.06%
EPS
+8.47%
Free cash flow
+69.5%
Total debt
+8.81%

Quarter to July 2026, against a year earlier

173.61 1.83 +1.07%
Market cap
$48.4B
P/E
33.8×
Fwd P/E
34.1×
Dividend yield
0.59%
F-score
5/9
Altman Z
5.46
Beneish M
−2.46
Dividend safety
86/100

Agilent Technologies, Inc. 10-Q filed Jun 1, 2026

Fiscal Q2 2026 · Period ended Apr 30, 2026 · Filed · accepted 4:09 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Mar 3, 2026: 18 added · 10 removed · 68 modified; 15 with only figures updated

  1. Modified

    The following discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included elsewhere in this Form 10-Q and our Annual Report on Form 10-K. This report contains forward-looking statements including, without limitation, statements regarding growth opportunities, including for and in our end markets, new product and service introductions, the position and strength of our businesses, products and services, market demand for and adoption of our products and solutions, the ability of our products and solutions to address customer needs and meet industry requirements, our focus on enhancing our customers’ experience, delivering differentiated product solutions and driving productivity improvements, leveraging our product platforms to maximize growth, our investments, including in manufacturing infrastructure, research and development and expanding and improving our applications and solutions portfolios, expanding our position in developing countries and emerging markets, our contributions to our defined benefit plans, our hedging programs and other actions to offset the effects of foreign currency and interest rate movements, our future effective tax rate, unrecognized tax benefits, reimbursement incentives, our ability to satisfy our liquidity requirements, including through cash generated from operations, the potential impact of adopting new accounting pronouncements, indemnification obligations, our sales, our purchase commitments, our capital expenditures, the integration, effects and timing of our acquisitions and other transactions, expense reduction and other results from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, the effects of geopolitical tensions, macroeconomic and market conditions, including relating to or arising from changes to tariffs, import/export or trade policies, the recovery and health of our end markets, seasonality, mix, future financial results, our operating margin, our geographical diversification, interest rates, inflationary pressures and local regulations and restrictions, that involve risks and uncertainties. Our actual results could differ materially from the results contemplated by these forward-looking statements due to various factors, including those discussed in Part II Item 1A and elsewhere in this Form 10-Q.